# US 11,433,070 B2 · Synergistic anti-inflammatory compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,070 B2
- Document ID: US11433070B2
- Status: Granted
- Kind: B2
- Application number: 16/913,183
- Filed: 2020-06-26
- Published: 2021-09-16
- Granted: 2022-09-06
- Earliest claimed: 2019-06-28
- Assignees: The Procter & Gamble Company
- Applicants: The Procter & Gamble Company
- Inventors: Jeanette Anthea Richards; James Robert Schwartz; Leo Timothy Laughlin, II; Geoffrey Marc Wise; Eric Scott Johnson
- Web page: https://patentgrep.com/patent/US11433070B2

## CPC

- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61Q 5/006: {Antidandruff preparations}
- A61K 8/4926: {having six membered rings}
- A61K 8/4953: {containing pyrimidine ring derivatives, e.g. minoxidil}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61P 17/10: Anti-acne agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to a personal care composition comprising a) azoxystrobin; b) a 2-pyridinol-N-oxide material wherein the ratio of a:b is from about 4:1 to about 1:50; wherein there is a synergistic anti-inflammatory/cellular stress activity.

## Claims

### Claim 1

A personal care composition comprising:
a) azoxystrobin;
b) a 2-pyridinol-N-oxide material
wherein the ratio of a:b is from about 4:1 to about 1:50; wherein there is a synergistic anti-inflammatory/cellular stress activity.

### Claim 2 (depends on 1)

A personal care according to claim 1 wherein the anti-inflammatory benefit is measured as PGE2 activity.

### Claim 3 (depends on 2)

A personal care composition according to claim 2 wherein the synergistic PGE2 activity is at least 1.5× higher than the individual PGE2 activity.

### Claim 4 (depends on 1)

A personal care composition according to claim 1 wherein the ratio of a:b is from about 1:1 to about 1:10.

### Claim 5 (depends on 1)

A personal care composition according to claim 1 wherein the personal care composition is selected from group consisting of a shampoo, conditioner, leave-on, tonic and mixtures thereof.

### Claim 6 (depends on 1)

A personal care composition according to claim 1 wherein the 2-pyridinol-N-oxide material is from about 0.05% to about 5%, by weight of the composition.

### Claim 7 (depends on 1)

A personal care composition according to claim 1 wherein the 2-pyridinol-N-oxide material is from about 0.3% to about 3%, by weight of the composition.

### Claim 8 (depends on 1)

A personal care composition according to claim 1 wherein the 2-pyridinol-N-oxide material is selected from the group consisting of 1-Hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone monoethanolamine salt, 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolammonium salt, 6-[[p-chlorophenoxy)phenoxyl]methyl]-1 hydroxy-4-methyl-pyridone.

### Claim 9 (depends on 8)

A personal care composition according to claim 8 wherein the 2-pyridinol-N-oxide material is piroctone olamine.

### Claim 10

A method of using a composition comprising
a) azoxystrobin;
b) a 2-pyridinol-N-oxide material;
wherein the ratio of a:b is from about 1:1 to about 1:10 to provide a synergistic anti-inflammatory/cellular stress activity.

### Claim 11

A method of using a composition comprising:
a) azoxystrobin;
b) a 2-pyridinol-N-oxide material;
wherein the ratio of a:b is from about 1:1 to about 1:10 to provide a synergistic anti-inflammatory/cellular stress activity wherein there is greater than a 20% reduction in PGE2 release compared to a baseline.